Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 0
---
Item 1. Financial Statements

CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

    September 30,  
    December 31, 

    2025  
    2024 

    (Unaudited)  

    ASSETS 

    Current assets: 

    Cash, restricted cash, and cash equivalents 
    $2,022,072  
    $3,327,060 
  
    Prepaid expenses and other current assets 
     531,827  
     274,749 
  
    Deferred offering costs 
     -  
     112,232 
  
    Total current assets 
     2,553,899  
     3,714,041 

    Deferred offering costs, net of current portion 
     174,505  
     500,000 
  
    Operating lease right-of-use assets 
     869,538  
     1,464,367 
  
    Property and equipment, net 
     313,452  
     528,521 
  
    Total assets 
    $3,911,394  
    $6,206,929 

    LIABILITIES AND STOCKHOLDERS’ DEFICIT 

    Current liabilities: 

    Accounts payable 
    $7,077,342  
    $4,507,318 
  
    Accrued liabilities 
     340,691  
     1,913,175 
  
    Operating lease liability 
     931,023  
     876,392 
  
    Earnout liability 
     20,000  
     20,000 
  
    Deemed dividend – common stock liability, 692 shares  
     85,500  
     85,500 
  
    Total current liabilities 
     8,454,556  
     7,402,385 

    Operating lease liability, net of current portion 
     -  
     699,107 
  
    Total liabilities 
     8,454,556  
     8,101,492 

    Commitments and contingencies 

    Stockholders’ deficit: 

    Series C convertible preferred stock, $0.0001 par value; 2,853 shares authorized; 7 and 2,853 shares issued and outstanding at September 30,